Clinical Impact of the Use of Warfarin in Patients with Atrial Fibrillation Undergoing Maintenance Hemodialysis
: We evaluated the impact of warfarin use on the clinical outcomes of patients with atrial fibrillation who were undergoing hemodialysis (HD). : A retrospective analysis was conducted utilizing data from patients undergoing maintenance HD who participated in HD quality assessment programs. Patients...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2024-04, Vol.13 (8), p.2404 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 2404 |
| container_title | Journal of clinical medicine |
| container_volume | 13 |
| creator | Kang, Seok Hui Kim, Gui Ok Kim, Bo Yeon Son, Eun Jung Do, Jun Young |
| description | : We evaluated the impact of warfarin use on the clinical outcomes of patients with atrial fibrillation who were undergoing hemodialysis (HD).
: A retrospective analysis was conducted utilizing data from patients undergoing maintenance HD who participated in HD quality assessment programs. Patients who were assigned the diagnostic code for atrial fibrillation (n = 4829) were included and divided into two groups based on the use of warfarin: No group (no warfarin prescriptions (n = 4009)), and Warfarin group (warfarin prescriptions (n = 820)).
: Cox regression analyses revealed that the hazard ratio for all-cause mortality in the Warfarin group was 1.15 (
= 0.005) in univariate analysis and 1.11 (
= 0.047) in multivariable analysis compared to that of the No group. Hemorrhagic stroke was significantly associated with warfarin use, but no significant association between the use of warfarin and ischemic stroke or cardiovascular events was observed. The subgroup results demonstrated similar trends.
: Warfarin use is associated with a higher risk of all-cause mortality and hemorrhagic stroke, and has a neutral effect on ischemic stroke and cardiovascular events in patients with atrial fibrillation who are undergoing HD, compared to those who are not using warfarin. |
| doi_str_mv | 10.3390/jcm13082404 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_3047949990</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A793559932</galeid><sourcerecordid>A793559932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-e221e6445f3ca277e1df9461c02eaa64d9667fe7708173ccf0e07996272823e63</originalsourceid><addsrcrecordid>eNptkd1LXDEQxUOpVFGf-l4CfSmU1Xxt5uZxWWoVLPWhSx8vMXeyZrk32SZZxP--WbRqS5NAhpnfGQ4cQt5zdialYecbN3HJOqGYekOOBAOYMdnJt6_qQ3Jayoa103VKcHhHDmWnQWrQRyQtxxCDsyO9mrbWVZo8rXdIVwX35U-bvc0h0vZubA0Ya6H3od7RRc2hqS7CbQ7j2EYp0lUcMK9TiGv6zYZYMdrokF7ilIYGP5RQTsiBt2PB06f_mKwuvvxYXs6uv3-9Wi6uZ06CqTMUgqNWau6lswIA-eCN0twxgdZqNRitwSMA6zhI5zxDBsZoAaITErU8Jp8e925z-rXDUvspFIfNacS0K71kCowyxrCGfvwH3aRdjs3dntKGAzPdC7W2I_Yh-lSzdful_QKMnM-NkaJRZ_-h2h1wCi5F9KH1_xJ8fhS4nErJ6PttDpPNDz1n_T7h_lXCjf7wZHV3O-HwzP7JU_4G9POeYA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3046917098</pqid></control><display><type>article</type><title>Clinical Impact of the Use of Warfarin in Patients with Atrial Fibrillation Undergoing Maintenance Hemodialysis</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kang, Seok Hui ; Kim, Gui Ok ; Kim, Bo Yeon ; Son, Eun Jung ; Do, Jun Young</creator><creatorcontrib>Kang, Seok Hui ; Kim, Gui Ok ; Kim, Bo Yeon ; Son, Eun Jung ; Do, Jun Young</creatorcontrib><description>: We evaluated the impact of warfarin use on the clinical outcomes of patients with atrial fibrillation who were undergoing hemodialysis (HD).
: A retrospective analysis was conducted utilizing data from patients undergoing maintenance HD who participated in HD quality assessment programs. Patients who were assigned the diagnostic code for atrial fibrillation (n = 4829) were included and divided into two groups based on the use of warfarin: No group (no warfarin prescriptions (n = 4009)), and Warfarin group (warfarin prescriptions (n = 820)).
: Cox regression analyses revealed that the hazard ratio for all-cause mortality in the Warfarin group was 1.15 (
= 0.005) in univariate analysis and 1.11 (
= 0.047) in multivariable analysis compared to that of the No group. Hemorrhagic stroke was significantly associated with warfarin use, but no significant association between the use of warfarin and ischemic stroke or cardiovascular events was observed. The subgroup results demonstrated similar trends.
: Warfarin use is associated with a higher risk of all-cause mortality and hemorrhagic stroke, and has a neutral effect on ischemic stroke and cardiovascular events in patients with atrial fibrillation who are undergoing HD, compared to those who are not using warfarin.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm13082404</identifier><identifier>PMID: 38673676</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Anticoagulants ; Aspirin ; Atrial fibrillation ; Body mass index ; Cardiac arrhythmia ; Codes ; Comorbidity ; Creatinine ; Diabetes ; Drug therapy ; Females ; Hemodialysis ; Hemodialysis patients ; Hemoglobin ; Ischemia ; Kidney diseases ; Mortality ; Patient outcomes ; Patients ; Peritoneal dialysis ; Phosphorus ; Proteins ; Regression analysis ; Stroke ; Survival analysis ; Venous access ; Warfarin</subject><ispartof>Journal of clinical medicine, 2024-04, Vol.13 (8), p.2404</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c379t-e221e6445f3ca277e1df9461c02eaa64d9667fe7708173ccf0e07996272823e63</cites><orcidid>0000-0002-6360-9310 ; 0000-0003-1023-0195</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38673676$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kang, Seok Hui</creatorcontrib><creatorcontrib>Kim, Gui Ok</creatorcontrib><creatorcontrib>Kim, Bo Yeon</creatorcontrib><creatorcontrib>Son, Eun Jung</creatorcontrib><creatorcontrib>Do, Jun Young</creatorcontrib><title>Clinical Impact of the Use of Warfarin in Patients with Atrial Fibrillation Undergoing Maintenance Hemodialysis</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>: We evaluated the impact of warfarin use on the clinical outcomes of patients with atrial fibrillation who were undergoing hemodialysis (HD).
: A retrospective analysis was conducted utilizing data from patients undergoing maintenance HD who participated in HD quality assessment programs. Patients who were assigned the diagnostic code for atrial fibrillation (n = 4829) were included and divided into two groups based on the use of warfarin: No group (no warfarin prescriptions (n = 4009)), and Warfarin group (warfarin prescriptions (n = 820)).
: Cox regression analyses revealed that the hazard ratio for all-cause mortality in the Warfarin group was 1.15 (
= 0.005) in univariate analysis and 1.11 (
= 0.047) in multivariable analysis compared to that of the No group. Hemorrhagic stroke was significantly associated with warfarin use, but no significant association between the use of warfarin and ischemic stroke or cardiovascular events was observed. The subgroup results demonstrated similar trends.
: Warfarin use is associated with a higher risk of all-cause mortality and hemorrhagic stroke, and has a neutral effect on ischemic stroke and cardiovascular events in patients with atrial fibrillation who are undergoing HD, compared to those who are not using warfarin.</description><subject>Anticoagulants</subject><subject>Aspirin</subject><subject>Atrial fibrillation</subject><subject>Body mass index</subject><subject>Cardiac arrhythmia</subject><subject>Codes</subject><subject>Comorbidity</subject><subject>Creatinine</subject><subject>Diabetes</subject><subject>Drug therapy</subject><subject>Females</subject><subject>Hemodialysis</subject><subject>Hemodialysis patients</subject><subject>Hemoglobin</subject><subject>Ischemia</subject><subject>Kidney diseases</subject><subject>Mortality</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Peritoneal dialysis</subject><subject>Phosphorus</subject><subject>Proteins</subject><subject>Regression analysis</subject><subject>Stroke</subject><subject>Survival analysis</subject><subject>Venous access</subject><subject>Warfarin</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkd1LXDEQxUOpVFGf-l4CfSmU1Xxt5uZxWWoVLPWhSx8vMXeyZrk32SZZxP--WbRqS5NAhpnfGQ4cQt5zdialYecbN3HJOqGYekOOBAOYMdnJt6_qQ3Jayoa103VKcHhHDmWnQWrQRyQtxxCDsyO9mrbWVZo8rXdIVwX35U-bvc0h0vZubA0Ya6H3od7RRc2hqS7CbQ7j2EYp0lUcMK9TiGv6zYZYMdrokF7ilIYGP5RQTsiBt2PB06f_mKwuvvxYXs6uv3-9Wi6uZ06CqTMUgqNWau6lswIA-eCN0twxgdZqNRitwSMA6zhI5zxDBsZoAaITErU8Jp8e925z-rXDUvspFIfNacS0K71kCowyxrCGfvwH3aRdjs3dntKGAzPdC7W2I_Yh-lSzdful_QKMnM-NkaJRZ_-h2h1wCi5F9KH1_xJ8fhS4nErJ6PttDpPNDz1n_T7h_lXCjf7wZHV3O-HwzP7JU_4G9POeYA</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Kang, Seok Hui</creator><creator>Kim, Gui Ok</creator><creator>Kim, Bo Yeon</creator><creator>Son, Eun Jung</creator><creator>Do, Jun Young</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6360-9310</orcidid><orcidid>https://orcid.org/0000-0003-1023-0195</orcidid></search><sort><creationdate>20240401</creationdate><title>Clinical Impact of the Use of Warfarin in Patients with Atrial Fibrillation Undergoing Maintenance Hemodialysis</title><author>Kang, Seok Hui ; Kim, Gui Ok ; Kim, Bo Yeon ; Son, Eun Jung ; Do, Jun Young</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-e221e6445f3ca277e1df9461c02eaa64d9667fe7708173ccf0e07996272823e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Anticoagulants</topic><topic>Aspirin</topic><topic>Atrial fibrillation</topic><topic>Body mass index</topic><topic>Cardiac arrhythmia</topic><topic>Codes</topic><topic>Comorbidity</topic><topic>Creatinine</topic><topic>Diabetes</topic><topic>Drug therapy</topic><topic>Females</topic><topic>Hemodialysis</topic><topic>Hemodialysis patients</topic><topic>Hemoglobin</topic><topic>Ischemia</topic><topic>Kidney diseases</topic><topic>Mortality</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Peritoneal dialysis</topic><topic>Phosphorus</topic><topic>Proteins</topic><topic>Regression analysis</topic><topic>Stroke</topic><topic>Survival analysis</topic><topic>Venous access</topic><topic>Warfarin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Seok Hui</creatorcontrib><creatorcontrib>Kim, Gui Ok</creatorcontrib><creatorcontrib>Kim, Bo Yeon</creatorcontrib><creatorcontrib>Son, Eun Jung</creatorcontrib><creatorcontrib>Do, Jun Young</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Seok Hui</au><au>Kim, Gui Ok</au><au>Kim, Bo Yeon</au><au>Son, Eun Jung</au><au>Do, Jun Young</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Impact of the Use of Warfarin in Patients with Atrial Fibrillation Undergoing Maintenance Hemodialysis</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>13</volume><issue>8</issue><spage>2404</spage><pages>2404-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>: We evaluated the impact of warfarin use on the clinical outcomes of patients with atrial fibrillation who were undergoing hemodialysis (HD).
: A retrospective analysis was conducted utilizing data from patients undergoing maintenance HD who participated in HD quality assessment programs. Patients who were assigned the diagnostic code for atrial fibrillation (n = 4829) were included and divided into two groups based on the use of warfarin: No group (no warfarin prescriptions (n = 4009)), and Warfarin group (warfarin prescriptions (n = 820)).
: Cox regression analyses revealed that the hazard ratio for all-cause mortality in the Warfarin group was 1.15 (
= 0.005) in univariate analysis and 1.11 (
= 0.047) in multivariable analysis compared to that of the No group. Hemorrhagic stroke was significantly associated with warfarin use, but no significant association between the use of warfarin and ischemic stroke or cardiovascular events was observed. The subgroup results demonstrated similar trends.
: Warfarin use is associated with a higher risk of all-cause mortality and hemorrhagic stroke, and has a neutral effect on ischemic stroke and cardiovascular events in patients with atrial fibrillation who are undergoing HD, compared to those who are not using warfarin.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38673676</pmid><doi>10.3390/jcm13082404</doi><orcidid>https://orcid.org/0000-0002-6360-9310</orcidid><orcidid>https://orcid.org/0000-0003-1023-0195</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2024-04, Vol.13 (8), p.2404 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3047949990 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Anticoagulants Aspirin Atrial fibrillation Body mass index Cardiac arrhythmia Codes Comorbidity Creatinine Diabetes Drug therapy Females Hemodialysis Hemodialysis patients Hemoglobin Ischemia Kidney diseases Mortality Patient outcomes Patients Peritoneal dialysis Phosphorus Proteins Regression analysis Stroke Survival analysis Venous access Warfarin |
| title | Clinical Impact of the Use of Warfarin in Patients with Atrial Fibrillation Undergoing Maintenance Hemodialysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T10%3A20%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Impact%20of%20the%20Use%20of%20Warfarin%20in%20Patients%20with%20Atrial%20Fibrillation%20Undergoing%20Maintenance%20Hemodialysis&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Kang,%20Seok%20Hui&rft.date=2024-04-01&rft.volume=13&rft.issue=8&rft.spage=2404&rft.pages=2404-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm13082404&rft_dat=%3Cgale_proqu%3EA793559932%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3046917098&rft_id=info:pmid/38673676&rft_galeid=A793559932&rfr_iscdi=true |